[Immune checkpoint inhibitors and endocrinological side effects]

Ugeskr Laeger. 2017 Dec 4;179(49):V05170362.
[Article in Danish]

Abstract

Immune checkpoint inhibitors including anti-cytotoxic T-lymphocyte-associated antigen-4 and anti-programmed cell death-1 have revolutionized cancer therapy but have also induced serious immune-related adverse events including hormonal dysfunction. The objective of this review is to characterize the incidence, clinical presentation, management and prognosis of the endocrine-related adverse events including hypophysitis, thyroid dysfunction and diabetes mellitus. Combination therapy is associated with an increased risk of adverse events. We recommend close monitoring of the hormone levels and glycaemic status during and a year after treatment.

Publication types

  • Review

MeSH terms

  • Addison Disease / chemically induced
  • Addison Disease / metabolism
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects*
  • Antineoplastic Agents, Immunological / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • CTLA-4 Antigen / antagonists & inhibitors
  • Diabetes Mellitus, Type 1 / chemically induced*
  • Diabetes Mellitus, Type 1 / metabolism
  • Female
  • Humans
  • Hypophysitis / chemically induced*
  • Hypophysitis / metabolism
  • Ipilimumab / administration & dosage
  • Ipilimumab / adverse effects*
  • Ipilimumab / therapeutic use
  • Male
  • Middle Aged
  • Neoplasms / drug therapy
  • Nivolumab / administration & dosage
  • Nivolumab / adverse effects*
  • Nivolumab / therapeutic use
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Thyroid Diseases / chemically induced*
  • Thyroid Diseases / metabolism

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • CTLA-4 Antigen
  • Ipilimumab
  • Programmed Cell Death 1 Receptor
  • Nivolumab